Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM.
Bachmann F, Schreder M, Engelhardt M, Langer C, Wolleschak D, Mügge LO, Dürk H, Schäfer-Eckart K, Blau IW, Gramatzki M, Liebisch P, Grube M, V Metzler I, Bassermann F, Metzner B, Röllig C, Hertenstein B, Khandanpour C, Dechow T, Hebart H, Jung W, Theurich S, Maschmeyer G, Salwender H, Hess G, Bittrich M, Rasche L, Brioli A, Eckardt KU, Straka C, Held S, Einsele H, Knop S. Bachmann F, et al. Among authors: brioli a. Cancers (Basel). 2021 Mar 16;13(6):1322. doi: 10.3390/cancers13061322. Cancers (Basel). 2021. PMID: 33809431 Free PMC article.
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO. Brioli A, et al. J Cancer Res Clin Oncol. 2020 Mar;146(3):749-759. doi: 10.1007/s00432-019-03101-z. Epub 2019 Dec 2. J Cancer Res Clin Oncol. 2020. PMID: 31788741 Clinical Trial.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study.
Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Crodel CC, et al. Among authors: brioli a. Leukemia. 2020 Nov;34(11):3106. doi: 10.1038/s41375-020-0970-2. Leukemia. 2020. PMID: 32651539 Free PMC article.
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M. Brioli A, et al. Leukemia. 2024 May;38(5):1072-1080. doi: 10.1038/s41375-024-02204-y. Epub 2024 Mar 28. Leukemia. 2024. PMID: 38548962 Free PMC article.
Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study.
Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Crodel CC, et al. Among authors: brioli a. Leukemia. 2020 Jul;34(7):1949-1953. doi: 10.1038/s41375-020-0890-1. Epub 2020 May 30. Leukemia. 2020. PMID: 32474573 Free PMC article. No abstract available.
Pomalidomide combinations are a safe and effective option after daratumumab failure.
Brioli A, Gengenbach L, Mancuso K, Binder M, Ernst T, Heidel FH, Stauch T, Zamagni E, Hilgendorf I, Hochhaus A, Engelhardt M, von Lilienfeld-Toal M. Brioli A, et al. J Cancer Res Clin Oncol. 2023 Aug;149(9):6569-6574. doi: 10.1007/s00432-023-04637-x. Epub 2023 Feb 13. J Cancer Res Clin Oncol. 2023. PMID: 36781500 Free PMC article.
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
Tosi P, Zamagni E, Tacchetti P, Ceccolini M, Perrone G, Brioli A, Pallotti MC, Pantani L, Petrucci A, Baccarani M, Cavo M. Tosi P, et al. Among authors: brioli a. Biol Blood Marrow Transplant. 2010 Aug;16(8):1115-21. doi: 10.1016/j.bbmt.2010.02.020. Epub 2010 Mar 1. Biol Blood Marrow Transplant. 2010. PMID: 20197100 Free article. Clinical Trial.
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C, Marzocchi G, Santoro A, Cavo M. Zannetti BA, et al. Among authors: brioli a. Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035. Am J Hematol. 2015. PMID: 25858483 Free article.
64 results